针对F-BOX蛋白质的抑制剂
Yalnaz Naseem1,2,3,4,5, Chaofeng Zhang1,2,3,4,5, Xinyi Zhou1,2,3,4,5
1School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Cell biochemistry and biophysics
|August 25, 2023
概括
F-box蛋白通过无处不在来调节细胞过程;突变导致形. 向F盒蛋白的抑制剂通过诱导癌细胞的亡,显示出对新型癌症疗法的希望.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 在瘤学瘤学.
背景情况:
- F-盒蛋白调解基质的无处不在和降解,对于细胞过程至关重要.
- F-box蛋白活性的失调与人类的发育不良和癌症的发展有关.
- 准F盒蛋白为各种癌症提供了潜在的治疗策略.
研究的目的:
- 探索F-box蛋白在恶性瘤中的作用.
- 审查F-box抑制剂及其在癌症治疗中的治疗潜力.
- 确定有希望的针对F-box蛋白和相关途径的抗癌策略.
主要方法:
- 关于F-盒蛋白功能和癌症的关键研究的文献综述.
- 在细胞过程中分析F-盒蛋白介导的蛋白解.
- 研究F盒抑制剂,包括NVD-BK M120,及其机制.
主要成果:
- F-box蛋白质与细胞增殖,细胞亡,侵袭,血管生成和转移有关.
- 作为FBW7抑制剂的NVD-BK M120,通过影响MCL1水平,诱导肺癌细胞的亡.
- F-box 抑制剂在某些癌症中显示出对特定突变蛋白的有效性.
结论:
- F-box蛋白在癌症的发展和进展中起着至关重要的作用.
- 向抑制F盒蛋白是开发新型抗癌疗法的一个有希望的途径.
- 对F-盒蛋白通路的进一步研究可以导致更有效的癌症治疗方法.
更多相关视频
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.2K
14:34Determination of Tripartite Interaction between Two Monomers of a MADS-box Transcription Factor and a Calcium Sensor Protein by BiFC-FRET-FLIM Assay
Published on: December 25, 2021
3.8K
相关概念视频
Protein Complexes with Interchangeable Parts
2.6K
Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
2.6K
Eukaryotic Transcription Inhibitors
9.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.9K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
